Comparing the current results to its competitors, Tenaya Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Tenaya Therapeutics Inc 's competitors' average revenue growth of 190.07 %, achieved in the same quarter.
Tenaya Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, which is characterized by rapidly advancing technologies and a strong emphasis on intellectual property. It faces competition from large and specialty pharmaceutical companies, biotechnology companies, academic research institutions, governmental agencies, and public and private research institutions. Its product candidates compete with existing therapies and those in development. For the product candidate TN-201, the primary competition is expected to come from programs targeting the underlying genetic cause of MYBPC3-associated hypertrophic cardiomyopathy (HCM). According to publicly available data, no treatments for this condition have yet received regulatory approval or entered clinical development. Competitors mentioned in filings include Alnylam.
November 25, 2024
Tenaya Therapeutics (NASDAQ: TNYA), a pioneering biotechnology company focusing on gene therapy and heart-related conditions, has announced the commencement of the RIDGE-1 Phase 1b clinical trial with the dosing of the first patient. This trial evaluates TN-401, an innovative AAV9-based gene therapy aimed at addressing Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) associated with PKP2 mutations. ARVC, a hereditary heart disorder characterized by the replacement of cardiac muscle with fibrous and fatty tissue, often leads to an increased risk of arrhythmias and sudden cardiac arrest. The condition is chiefly associated with mutations in the Plakophilin-2 (PKP2) gene, obstructing proper protein produc...
Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.
Sources:
Tenaya Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tenaya Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
